BIOTECHNOLOGY VALUE FUND II LP
CIK 1102444 · last filed 2026-01-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.12B
Companies
20
Total Filings
45
Lifetime Open-Market Net
$588.97M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 62,383 | $15.70 | $979.4K | $0 | 1 | 2025-06-17 | |
| MLTX | Director | 10,235,089 | $18.69 | $191.29M | $0 | 1 | 2025-06-09 |
| Repare Therapeutics Inc. (RPTX) Delisted | 3,792,157 | $2.65 | $10.05M | $28.21M | 1 | 2023-11-03 | |
| KYMR | 1,900,272 | $86.20 | $163.81M | $306.52M | 3 | 2022-01-31 | |
| RAIN | 1,479,460 | $2.04 | $3.02M | $21.20M | 3 | 2021-09-23 | |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 4,336,875 | $38.00 | $164.80M | $33.14M | 2 | 2020-10-08 | |
| XOMA | 10%+ Owner | 1,948,819 | $41.79 | $81.44M | $21.66M | 6 | 2020-09-01 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 314,139 | $13.60 | $4.27M | -$1.57M | 1 | 2019-09-10 | |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 6,372,596 | $0.04 | $284.9K | $20.07M | 2 | 2018-11-21 |
| SNDX | 85,038 | $18.25 | $1.55M | $0 | 1 | 2018-06-20 | |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | 1,898,293 | — | — | $3.08M | 4 | 2015-02-09 | |
| CCXI | 485,412 | $10.22 | $4.96M | $11.62M | 1 | 2013-09-13 | |
| NBIX | 756,600 | $159.76 | $120.87M | $2.48M | 1 | 2011-10-12 | |
| CAPS | 951,800 | $0.29 | $280.8K | $1.55M | 2 | 2011-08-22 | |
| Celera CORP (CRA) Delisted | 31,520,834 | — | — | $155.25M | 4 | 2011-05-10 | |
| AVIGEN INC \DE (AVGN) Delisted | 15,674,378 | — | — | -$5.6K | 1 | 2009-11-20 | |
| RPRX | 8,583,102 | $54.87 | $470.95M | -$3.60M | 1 | 2009-09-24 | |
| CRIS | 8,194,716 | $0.42 | $3.45M | -$17.08M | 1 | 2009-04-29 | |
| LGND | 10%+ Owner | 15,978,207 | $255.54 | $4.08B | $5.66M | 5 | 2009-01-27 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 8,135,099 | — | — | $773.0K | 1 | 2008-11-12 |
Recent Filings · Page 2 of 5
45 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-04-27 | RAIN | Mixed | +49,286,040 | $191.03M | EDGAR |
| 2020-10-08 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +3,452,410 | $17.38M | EDGAR |
| 2020-09-01 | XOMA | Buy (P) | +356,210 | $6.66M | EDGAR |
| 2020-03-20 | XOMA | Buy (P) | +44,390 | $644.7K | EDGAR |
| 2019-10-08 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +4,210,374 | $15.76M | EDGAR |
| 2019-09-10 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Sell (S) | −350,000 | -$1.57M | EDGAR |
| 2018-12-04 | XOMA | Buy (P) | +68,600 | $1.02M | EDGAR |
| 2018-11-29 | XOMA | Buy (P) | +207,900 | $3.14M | EDGAR |
| 2018-11-21 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +10,288,782 | $14.08M | EDGAR |
| 2018-11-21 | XOMA | Buy (P) | +505,771 | $7.17M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.